Transoral Robot-Assisted Surgery in Supraglottic and Oropharyngeal Squamous Cell Carcinoma: Laser Versus Monopolar Electrocautery

Marco Benazzo 1, Pietro Canzi 1,*, Simone Mauramati 1, Fabio Sovardi 1, Antonio Occhini 1, Eugenia Maiorano 1, Giuseppe Trisolini 1 and Patrizia Morbini 2

1 Department of Otorhinolaryngology, University of Pavia, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy; marco.benazzo@unipv.it (M.B.); simone.mauramati@gmail.com (S.M.); sovardi.fabio@gmail.com (F.S.); antonio.occhini@alice.it (A.O.); eugenia_maiorano@libero.it (E.M.); giuseppe.trisolini01@universitadipavia.it (G.T.)

2 Unit of Pathology, Department of Molecular Medicine, University of Pavia, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy; patrizia.morbini@unipv.it

* Correspondence: pietro.canzi@unipv.it; Tel.: +39-3289573636; Fax: +39-0382-528184

Received: 30 October 2019; Accepted: 4 December 2019; Published: 7 December 2019

Abstract: Background: Monopolar electrocautery (EC) is the surgical cutting and haemostatic tool most commonly used for transoral robotic surgery (TORS). The aim of this study was to retrospectively compare EC efficacy in the treatment of patients affected by T1 or T2 oropharyngeal and supraglottic squamous cell carcinomas with the more recently introduced laser fibres. Methods: We considered all TORS patients admitted to our department from January 2010 to June 2019. The outcomes of patients treated with Thulium: yttrium aluminium garnet (YAG) laser (TY-TORS), CO2 laser (CO2-TORS) and EC (EC-TORS) were analysed in order to assess surgical performances, functional outcomes and postoperative complications. Results: Twenty patients satisfied the enrolling criteria, of which nine underwent laser-TORS, and the remaining 11 underwent EC-TORS. In all candidates, TORS procedures were completed without the need for microscopic/open conversion. Close or positive margins were significantly more frequent in EC-TORS (p = 0.028). A considerable difference was found in overall functional parameters: times of nasogastric tube and tracheostomy removal and time of hospital discharge were significantly shorter in laser-TORS (p = 0.04, p = 0.05, p = 0.04, respectively). Conclusions: Laser-TORS showed better results in comparison with EC-TORS in term of tumour resection margins and patient functional outcomes. Our findings can be justified with the greater tissue thermal damage caused by EC-TORS, despite prospective randomized trials and increased patient numbers being needed to confirm these preliminary conclusions.

Keywords: transoral robotic surgery; thulium laser; CO2 laser; cancer

1. Introduction

Since its first introduction in head and neck surgery [1], the transoral robotic approach has represented an effective and validated option in the management of T1 or T2 oropharyngeal and supraglottic tumours [2,3]. The comparison of the relative outcomes of the different therapeutic strategies available to treat these cancers (robotic surgery, transoral laser microsurgery, chemo-radiotherapy) is important to assess the best disease management and the optimal functional organ preservation for each case. Wide and 3D operative visualization, multidirectional and angled surgical motion, and intuitive and fast learning use are only some of the many advantages of transoral robotic surgery (TORS). Monopolar electrocautery is the most commonly used surgical cutting and haemostatic tool for TORS [1]. However, as a consequence of the limits of this instrument, new tools
have been implemented in recent years [4]. In fact, the relatively high thermal damage and tissue necrosis related to the monopolar electrocautery (EC) may negatively influence the oncologic and functional results in terms of tumour resection, quality of life and postoperative complications [4,5]. The recent development of flexible laser fibres has at last extended their use to TORS, with the aim of overcoming most EC limits [6]. Diode thulium: yttrium aluminium garnet (YAG) laser (TY) has been the first to be approved to be coupled with robotic technology [4]. We previously explored the feasibility of flexible thulium laser coupling with a novel robotic introducer for the treatment upper aerodigestive cancers [7]. More recently, flexible carbon dioxide (CO\textsubscript{2}) laser fibres have been developed to be suited for TORS, in order to reduce the severity of thermal damage. In current literature, few clinical trials have compared the outcomes of laser-TORS (CO\textsubscript{2}-TORS or TY-TORS) with EC-TORS [8,9]. Up to now, only one study reported data concerning surgical margins status [8]. The aim of the present study was to retrospectively assess laser benefits and outcomes in comparison with EC in patients affected by T1 or T2 oropharyngeal and supraglottic squamous cell carcinoma submitted to TORS.

2. Materials and Methods

We retrospectively analysed all patients who underwent TORS for treatment of pharyngolaryngeal tumours at the Otorhinolaryngology Department of Policlinico S. Matteo and University of Pavia (Italy) from January 2010 to June 2019, following institutional review board approval. Inclusion criteria are summarised as follows:

1. All patients consecutively scheduled for TORS with laser (TY- or CO\textsubscript{2}- laser) or EC, performed by the same surgeon team (M.B. and A.O.).
2. cT1/T2 oropharyngeal and supraglottic squamous cell carcinomas, cN0/2 (according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition) [10].
3. cM0 at oncological staging including panendoscopic biopsies of the upper aerodigestive tract, head and neck/chest Computed Tomography (CT) scan, and Magnetic Resonance Imaging (MRI) as needed.

All patients were preoperatively counselled about the conventional alternatives and signed informed consent was obtained. Surgical robotic set-up was predisposed as previously reported [7], and included:

- An Intuitive da Vinci S System (Intuitive Surgical, Inc., Sunnyvale, CA, USA);
- An Intuitive Surgical® Endo Wrist Introducer, 5Fr, to hold and position the thulium surgical laser fibres (Revolix Jr, LISA Laser, Katlenburg-Lindau, Germany). The power setting of a 2 µm continuous-wave TY ranged between 5.0 and 8.5 W during respectively margin incision and lesion removal;
- Flexible CO\textsubscript{2} Laser Fibre (OmniGuide Surgical, Lexington, MA, USA) inserted in a flexible metal carrier (grasped with Maryland atraumatic forceps). The CO\textsubscript{2} laser power was set to 14 W for dissection and 7 W for coagulation;
- A 5-mm monopolar EC (Intuitive Surgical, Erbotom ICC 350 ERBE Elektromedizin GmbH, Tübingen, Germany);
- A 5-mm Maryland forceps (EndoWrist; Intuitive Surgical, Inc);
- A Feyh-Kastenbauer retractor (Gyrus Medical Inc., Maple Grove, MN, USA).

The cutting tool (TY-laser, CO\textsubscript{2}-laser or EC) was handled in the left or right robotic arm relative to patient anatomy, independently of the surgeon handedness.

Recorded outcomes were analysed in order to assess three categories of results: surgical performances (surgical robotic time (SRT), estimated blood loss (EBL), status of tumour resection margins at histopathological evaluation, need for microscopic/open conversion), functional outcomes (oral diet recovery, time to tracheostomy removal, time to discharge), and postoperative complications. Adjuvant therapy included intensity modulated radiotherapy with or without chemotherapy.
Indications for these treatments were the presence of neck disease with multiple positive lymph nodes, extracapsular extension, and atypical metastatic patterns. Indications related to the primary tumour included histopathological evidence of lymphovascular invasion, positive resection margins, and perineural invasion. The decision for adjuvant therapy was based on multidisciplinary tumour board discussion of the case.

Medcalc Version 19.0.5 (MedCalc Software, Ostend, Belgium) was used for statistical analysis. Continuous variables were compared using a Kruskal–Wallis test. Categorical data were presented as frequencies and compared, using Fisher’s exact test to obtain the \( p \) value.

3. Results

Twenty patients (10 men and 10 women) aged 38–84 years (mean = 61.7 years) underwent TORS for supraglottic and oropharyngeal squamous cell carcinoma (Table 1). Nine patients underwent laser-TORS, two for supraglottic and seven for oropharyngeal tumours. Only one patient, affected by an oropharyngeal squamous cell carcinoma, underwent TORS surgery with CO\(_2\) laser, while the other eight patients were treated with thulium:YAG laser TORS. The remaining 11 patients underwent EC-TORS, two for supraglottic and nine for oropharyngeal tumours (Tables 2 and 3).

The two patient groups had comparable TNM tumour stage distribution but for supraglottic cancers. The TY-TORS group included only T1 cancers. Each surgical procedure was performed under general endotracheal anesthesia. All approaches were completed without the need for conversion to a microscopic/open procedure. Unilateral or bilateral selective neck dissection was performed using an open approach, in all cases, at the same time as TORS: eight patients were subjected to unilateral selective neck dissection and 10 to bilateral neck dissection. While nine patients were only treated with surgery, 11 patients needed adjuvant treatment (radiotherapy in five cases, chemotherapy in two, chemo-radiotherapy in four). In the laser-TORS group, no intraoperative adverse event occurred in patients treated for oropharyngeal squamous cell carcinoma; good bleeding control was always achieved. Only one postoperative complication was observed in this group, consisting of postoperative bleeding in a patient treated for squamous cell carcinoma (SCC) of the tongue base. Bleeding was stopped with electrocautery. Complications related to EC-TORS included three postoperative oropharyngeal hemorrhages and one intraoperative pharyngotomy (treated harvesting a sternocleidomastoid pedicled muscle flap).

In patients treated with laser-TORS for supraglottic SCC no operative/postoperative complications were reported; in those treated with EC-TORS, one postoperative cardiac arrest was observed, which resulted in a longer postoperative recovery time.

In the laser-TORS group, the mean follow-up for patients treated for oropharyngeal SCC was 77.4 months (±31.5 months). No patient was lost to follow-up. In the EC-TORS group the mean follow-up was 57.6 months (±24.0 months); one patient died, and one was lost to follow up. In patients treated for supraglottic SCC, the mean follow-ups were 105 months (±9.9 months) for TY-TORS and 57 months (±12.7 months) for EC-TORS. No patient was lost to follow-up. All patients were alive without evidence of disease at the time of last follow-up. Comparative outcomes focusing on main surgical and clinical variables are summarized in Tables 4 and 5.

The comparison of outcome measures was possible between global laser-TORS and EC-TORS populations; comparison was also possible in the subgroups of patients affected by oropharyngeal SCC. The comparison between the two TORS modalities was not possible for patients affected by supraglottic carcinoma due to the insufficient number of patients.

The average length of robotic excision and the estimated blood loss (EBL) were similar in EC and laser groups. The average hospital stay was significantly shorter for laser-TORS patients than for EC-TORS (9.8 vs. 13.8 days, \( p = 0.05 \)).
Table 1. Demographic and clinical data of the patients.

| Patient No. | Robotic Resection Tool | Years | Sex | Tumour Subsites | Histology | cTNM (AJCC) | Neck Dissection | Preceding Months | Subsites | Histology | TNM (AJCC) | Therapy | IID cm |
|-------------|------------------------|-------|-----|-----------------|-----------|-------------|-----------------|-----------------|----------|-----------|------------|---------|--------|
| 1           | TY                     | 62    | F   | Epiglottis      | SCC G2    | c T1N0M0    | L,R, II-III-IV  | 24              | L tonsil and L tongue base | SCC G3     | pT2N0M0  | RT-CH  |
| 2           | TY                     | 54    | F   | Epiglottis      | SCC G1    | c T1N2aM0   | L,R, II-III-IV  | 24              | L, I-II-III-IV | SCC G3     | pT2N1M0  | RT-CH  |
| 3           | TY                     | 48    | M   | L, lateral oropharyngeal wall | SCC G3 | c T1N0M0 | L, I-II-III-IV | 24              | L, hypopharynx | SCC G3     | pT2N1M0  | 4.0     |
| 4           | TY                     | 55    | M   | R, tongue base  | SCC G2    | c T1N0M0    | L,R, I-II-III-IV| 24              | L, hypopharynx | SCC G3     | pT2N1M0  | RT-CH  |
| 5           | TY                     | 68    | F   | R, tongue base  | SCC G2    | c T1N1M0    | R,L, I-II-III-IV| 24              | L, neck     | SCC G2     | pTxN1M0  | L, ND   |
| 6           | TY                     | 56    | F   | L, tongue base  | SCC G2    | c T1N0M0    | R,L, I-II-III-IV| 24              | L, submandibular gland | Adenoid-cystic | pT1N0M0  | L, ND   |
| 7           | TY                     | 65    | F   | L, tongue base  | SCC G2    | c T2N0M0    | L, I-II-III-IV  | 24              | L, submandibular gland | Adenoid-cystic | pT1N0M0  | L, ND   |
| 8           | TY                     | 58    | M   | L, lateral oropharyngeal wall | SCC G2 | c T2N1M0 | L, II-III-IV  | 24              | Larynx   | SCC G2     | pT2N0M0   | Laryngectomy, L, ND |
| 9           | EC                     | 48    | M   | L, tonsil       | SCC G2    | c T1N0M0    | L, II-III-IV   | 24              | Larynx   | SCC G2     | pT2N0M0   | Laryngectomy, L, ND |
| 10          | EC                     | 52    | F   | L, tonsil       | SCC G2    | c T1N1M0    | L, I-II-III-IV  | 24              | Larynx   | SCC G2     | pT2N0M0   | Laryngectomy, L, ND |
| 11          | EC                     | 84    | M   | L, tonsil       | SCC G2    | c T2N2bM0   | L, I-II-III-IV  | 24              | Larynx   | SCC G2     | pT2N0M0   | Laryngectomy, L, ND |
| 12          | EC                     | 56    | M   | R, tongue base  | SCC G2    | c T2N2bM0   | R, I-II-III-IV  | 24              | Larynx   | SCC G2     | pT2N0M0   | Laryngectomy, L, ND |
| 13          | EC                     | 61    | F   | R, tonsil       | SCC G2    | c T2N1M0    | R,L, I-II-III-IV| 24              | Larynx   | SCC G2     | pT2N0M0   | Laryngectomy, L, ND |
| 14          | EC                     | 72    | M   | R, tonsil       | SCC G2    | c T2N1M0    | R,L, I-II-III-IV| 24              | Larynx   | SCC G2     | pT2N0M0   | Laryngectomy, L, ND |
| 15          | EC                     | 77    | M   | R, tonsil       | SCC G2    | c T1N1M0    | R, II-III-IV   | 24              | Larynx   | SCC G2     | pT2N0M0   | 4.3      |
| 16          | EC                     | 55    | F   | Epiglottis      | SCC G2    | c T2N2aM0   | R,L, II-III-IV  | 24              | Larynx   | SCC G2     | pT2N0M0   | 4.3      |
| 17          | EC                     | 79    | M   | Epiglottis      | SCC G2    | c T1N0M0    | R,L, II-III-IV  | 24              | Larynx   | SCC G2     | pT2N0M0   | 4.3      |
| 18          | EC                     | 72    | F   | R, tongue base  | SCC G2    | cT1N0M0     | c T2N1M0       | 24              | Larynx   | SCC G2     | pT2N0M0   | Laryngectomy, L, ND |
| 19          | EC                     | 52    | F   | L, tonsil       | SCC G2    | cT1N0M0     | c T2N1M0       | 24              | Larynx   | SCC G2     | pT2N0M0   | Laryngectomy, L, ND |
| 20          | CO₂                    | 59    | M   | R, tonsil       | SCC       | cT2N1M0     | R,I,II-III-IV  | 24              | Larynx   | SCC G2     | pT3N1M0   | 4.3      |

M = male, F = female, L = left, R = right, IID = interincisor distance, ND = neck dissection, TY = Thulium: yttrium aluminium garnet (YAG) laser, EC = monopolar electrocautery, SCC = squamous cell carcinoma, RT = radiotherapy, CH = chemotherapy, AJCC = American Joint Committee on Cancer.
Table 2. Patients’ operative and clinical data (oropharynx).

| Robotic Resection Tool | Patient No. | SRT (min) | EBL (mL) | Tumour Subsites | Oral Diet, Days | Time to Tracheostomy Removal, Days | Time to Discharge Days | Complications | Margins | Postoperative Treatment | pTNM | Follow-Up, Months |
|------------------------|-------------|-----------|----------|-----------------|----------------|-----------------------------------|-----------------------|---------------|---------|------------------------|------|---------------------|
| TY                     | 3           | 55        | 10       | L, lateral oropharyngeal wall | 4               | 7                                 | 7                     |               | negative | NO                     | p T1N0M0 | 96                   |
| TY                     | 4           | 40        | 30       | R, tongue base | 5               | 7                                 | 8                     | Day 22: bleeding stopped with electrocautery control | negative | NO                     | p T1N0M0 | 85                   |
| TY                     | 5           | 50        | 10       | R, tongue base | 4               | 5                                 | 7                     |               | negative | RT                     | p T1N1M0 | 82                   |
| TY                     | 6           | 35        | 25       | L, tongue base | 6               | 11                                | 13                    |               | negative | NO                     | p T1N0M0 | 78                   |
| TY                     | 7           | 40        | 30       | L, tongue base | 6               | 7                                 | 9                     |               | negative | NO                     | p T2N0M0 | 76                   |
| TY                     | 8           | 50        | 40       | L, tongue base | 3               | 6                                 | 7                     |               | negative | CH-RT                  | p T2N1M0 | 69                   |
| CO₂                   | 20          | 40        | 20       | R, tonsil | 6               | 7                                 | 8                     |               | positive | CH-RT                  | p T3N1M0 | 1                    |
| EC                     | 9           | 50        | 45       | R, lateral oropharyngeal wall | 8               | 12                                | 13                    |               | close     | CH                     | p T1N0M0 | 98                   |
| EC                     | 10          | 40        | 35       | L, tonsil | 6               | 7                                 | 10                    |               | negative | RT-CH                  | p T1N1M0 | 95                   |
| EC                     | 11          | 50        | 25       | L, tonsil | 5               | 4                                 | 19                    |               | positive | RT                     | p T2N2bM0 | 52                   |
| EC                     | 12          | 55        | 35       | R, tongue base | 9               | 13                                | 13                    | Intraoperative pharyngotomy Day 12: bleeding stopped with electrocautery control | negative | CH                     | p T2N1M0 | 43                   |
| EC                     | 13          | 40        | 30       | R, tonsil | 9               | 9                                 | 11                    | Day 12: bleeding stopped with electrocautery control | negative | CH                     | p T2N1M0 | 70                   |
| EC                     | 14          | 45        | 10       | R, tonsil | 2               | 9                                 | 9                     | Day 11: bleeding stopped with electrocautery control | positive | RT                     | p T2N2aM0 | 57                   |
| EC                     | 15          | 40        | 45       | R, tonsil | 5               | 7                                 | 8                     | Day 11: bleeding stopped with electrocautery control | negative | RT                     | p T1N1M0 | 54                   |
| EC                     | 18          | 45        | 25       | R, tongue base | 15              | 16                                | 20                    |               | positive | open surgery          | p T1N0MO | 18                   |
| EC                     | 19          | 35        | 35       | L, tonsil | 9               | 9                                 | 11                    |               | negative |                         | p T1N0MO | 33                   |

L = left, R = right, SRT = surgical robotic time, EBL = estimated blood loss, RT = radiotherapy, CH = chemotherapy.
Table 3. Patients’ operative and clinical data (larynx).

| Robotic Resection Tool | Patient No. | SRT, min | EBL, mL | Tumour Subsites | Oral Diet, Days | Time to Tracheostomy Removal, Days | Time to discharge, days | Complications | Margins | Postoperative Treatment | pTNM | Follow-Up, Months |
|------------------------|-------------|----------|---------|----------------|----------------|-----------------------------------|------------------------|--------------|---------|-----------------------|------|---------------------|
| TY                     | 1           | 135      | 35      | Epiglottis     | 6              | 8                                 | 15                     | negative     | NO      | pT1N0M0               |     | 112                 |
| TY                     | 2           | 110      | 20      | Epiglottis     | 5              | 7                                 | 14                     | negative     | NO      | pT1N0M0               |     | 98                  |
| EC                     | 16          | 130      | 40      | Epiglottis     | 10             | 12                                | 14                     | positive     | CH-RT  | pT2N1M0              |     | 66                  |
| EC                     | 17          | 120      | 30      | Epiglottis     | 18             | 20                                | 24                     | Day 7: cardiac arrest | negative | NO      | pT1N0M0               |     | 48                  |

SRT = surgical robotic time, EBL = estimated blood loss, RT = radiotherapy, CH = chemotherapy, TY = Thulium: yttrium aluminium garnet (YAG) laser, EC = monopolar electrocautery.

Table 4. Laser transoral robotic surgery (laser-TORS) versus monopolar electrocautery (EC-TORS) (oropharynx).

| Robotic Resection Tool | SRT, min (Mean) | EBL, mL (Mean) | Oral Diet, Days (Mean) | Time to Tracheostomy Removal, Days (Mean) | Time to Discharge, Days (Mean) | Postoperative Complications | Tumour Margins |
|------------------------|-----------------|----------------|------------------------|----------------------------------------|-----------------------------|-------------------------------|----------------|
| Laser-TORS (n = 7)     | 44.3 ± 7.3      | 23.6 ± 11.1    | 4.9 ± 1.2              | 7.1 ± 1.9                              | 8.4 ± 2.1                   | 1                            | 5, Positive, No, Negative, Close |
| EC-TORS (n = 9)        | 44.4 ± 6.3      | 31.7 ± 10.9    | 7.5 ± 3.7              | 9.5 ± 3.6                              | 12.7 ± 4.2                  | 2                            | 5, Positive, No, Negative, Close |

SRT = surgical robotic time, EBL = estimated blood loss, Laser-TORS = Laser transoral robotic surgery, EC-TORS = monopolar electrocautery transoral robotic surgery

Table 5. TY-TORS versus EC-TORS (larynx).

| Robotic Resection Tool | SRT, min (Mean) | EBL, mL (Mean) | Oral Diet, Days (Mean) | Time to Tracheostomy Removal, Days (Mean) | Time to Discharge, Days (Mean) | Postoperative Complications | Tumour Margins |
|------------------------|-----------------|----------------|------------------------|----------------------------------------|-----------------------------|-------------------------------|----------------|
| TY-TORS (n = 2)        | 122             | 27.5           | 5.5                    | 7.5                                    | 14.5                        | 0                            | 2, Positive, No, Negative, Close |
| EC-TORS (n = 2)        | 125             | 35             | 14                     | 16                                     | 19                          | 1                            | 1, Positive, No, Negative, Close |

SRT = surgical robotic time, EBL = estimated blood loss, TY-TORS = Thulium:YAG laser transoral robotic surgery, EC-TORS = monopolar electrocautery transoral robotic surgery
The mean times to nasogastric tube and tracheotomy removal were 5 and 7.2 days in laser group, respectively, and 8.7 and 9.8 days in EC group, respectively ($p = 0.04$).

Close or positive margins were observed more frequently in the EC group than in laser group ($p = 0.028$): in the EC-TORS group, four patients had positive resection margins (three oropharyngeal SCC and one supraglottic SCC), and two patients had close (i.e., <5 mm) resection margins; in laser-TORS only one patient had positive margin. No significant difference in complication rates have been observed.

When we compare oropharyngeal resection to supraglottic laryngectomy, the surgical robotic time resulted significantly longer for the second procedure ($p = 0.002$). Moreover, patients treated with supraglottic laryngectomy had a significantly longer hospital stay ($p = 0.013$). No differences were recorded in EBL and time to nasogastric tube and tracheostomy removal.

4. Discussion

Laser technology has represented an important step forward for head and neck surgery. In spite of the considerable advantages fulfilled by this technology, linear beam cutting has initially represented the main limitation to a more widespread use of this instrument. The introduction of flexible optical fibres capable of conveying this type of energy has allowed to expand laser applications and to integrate them with robot-assisted surgery.

Robotic surgery has been widely adopted across several specialties thanks to its numerous advantages, including shorter operating times, shorter hospital stays, and fewer intra- and postoperative complications as compared with traditional surgery. One of the main fields of application of robotic surgery in head and neck pathology is TORS [1,11]. The great oncological and functional results obtained by TORS in the treatment of early pharyngolaryngeal cancers have strongly encouraged its spread, providing numerous confirmations of feasibility [7,12,13], but also highlighting its limitations and the need for new tools to achieve even better outcomes [14].

Different cutting and haemostatic tools have been developed in order to limit tissue injury and induce a favourable wound healing process. Hoffman et al. [4] evaluated and compared the performances of four different instruments (Laser CO$_2$, Tm:YAG laser, monopolar electrocautery, radiofrequency needle) on a porcine model, focusing on the width of incision and coagulation zones, bleeding, tissue sticking, user friendliness, speed and costs. However, the comparison of functional and oncological results obtained by different tools in surgical practice is a fundamental step for a conscious preoperative evaluation of the cost–benefit ratio. Current literature provides a limited number of studies dealing with this topic. In particular, Karaman et al. [9], performed a systematic and quantitative comparison between CO$_2$-TORS and EC-TORS in a population of 20 patients who underwent tongue base resection for sleep apnoea syndrome. In their study, laser-TORS resulted in less intraoperative bleeding, shorter robot operating time, shorter lengths of hospitalization, shorter feeding rehabilitation and less postoperative pain, when compared with EC-TORS. Previously, Van Abel et al. [8] reported a comparison of TY-TORS (15 patients) with EC-TORS (30 patients); the use of thulium laser resulted in less postoperative pain, which may be due to decreased collateral thermal damage, and finer cutting [8].

In our study, we compared EC-TORS with laser-TORS focusing not only on functional but also on oncological results in a population of 20 patients affected by pharyngolaryngeal cancers. Despite the limits intrinsic to a retrospective type of analysis, our findings provided some interesting data. First of all, both approaches allowed successful completion of the surgical procedure in all patients, without requirement for microscopic or open conversion. SRT and EBL data were similar to those reported in literature and did not differ among the two groups [8,9,12], as well as rates of postoperative bleeding and frequency of airway complications. Positive margins were more frequent in EC-TORS, even though they did not seem to impact on survival or recurrence rate. However, considerable differences in overall functional parameters were observed, including time of discharge, and times of nasogastric tube and tracheostomy removal, which were significantly shorter in laser-TORS. This result confirms previous observations in a non-oncological setting [9].
The reported differences between laser and EC-TORS can be related to the different electrocautery properties of the two cutting modalities: the greater thermal energy delivered by EC-TORS and the resulting tissue necrosis can justify the worse functional parameters observed in comparison with laser-TORS. The higher rate of positive margins on histology may be due to a more extensive loss of tissue in consequence of energy transfer, which reduces the extension of “safe tissue” that can be observed at the periphery of the neoplastic lesion on the resected specimen.

In order to confirm these initial findings, further prospective randomized trials and a large number of patients are needed, in particular to analyse the subgroup of supraglottic cancers, whose number was too limited for statistical evaluation.

5. Conclusions

Despite the limited number of cases available for the study, laser-TORS showed better results in comparison with EC-TORS in term of tumour resection margins and functional outcomes. Less severe thermal injury and more precise cutting properties of flexible laser fibres may offer significant advantages in transoral treatment of early stage oropharyngeal and supraglottic cancers.

Author Contributions: M.B., P.C. and S.M. conceived and designed the study; M.B. and A.O. performed the surgery; F.S. and P.M. analyzed the data; P.C., S.M., F.S., G.T. and P.M. wrote the paper; P.C., F.S., G.T. and E.M. edited the paper.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. O’Malley, B.W.; Weinstein, G.S.; Snyder, Wand Hockstein, N.G. Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 2006, 116, 1465–1472.
2. Sinclair, C.F.; McColloch, N.L.; Carroll, W.R.; Rosenthal, E.L.; Desmond, R.A.; Magnuson, J.S. Patient-perceived and objective functional outcomes following transoral robotic surgery for early oropharyngeal carcinoma. Arch. Otolaryngol. Head Neck Surg. 2011, 137, 1112–1116. [CrossRef] [PubMed]
3. Olsen, S.M.; Moore, E.J.; Koch, C.A.; Price, D.L.; Kasperbauer, J.L.; Olsen, K.D. Transoral robotic surgery for supraglottic squamous cell carcinoma. Am. J. Otolaryngol. Head Neck Med. Surg. 2012, 33, 379–384. [CrossRef] [PubMed]
4. Hoffmann, T.K.; Schuler, P.J.; Bankfalvi, A.; Greve, J.; Heusgen, L.; Lang, S.; Mattheis, S. Comparative analysis of resection tools suited for transoral robot-assisted surgery. Eur. Arch. OtoRinoLaryngol. 2014, 271, 1207–1213. [CrossRef] [PubMed]
5. Liboon, J.; Funkhouser, W.; Terris, D.J. A Comparison of Mucosal Incisions Made by Scalpel, CO2 Laser, Electrocautery, and Constant-Voltage Electrocautery. Otolaryngol Head Neck Surg 1997, 5, 379–385. [CrossRef]
6. Durmus, K.; Kucur, C.; Uysal, I.O.; Dziegielewski, P.T.; Ozer, E. Feasibility and clinical outcomes of transoral robotic surgery and transoral robot-assisted carbon dioxide laser for hypopharyngeal carcinoma. J. Craniofac. Surg. 2015, 26, 235–237. [CrossRef] [PubMed]
7. Benazzo, M.; Canzi, P.; Occhini, A. Transoral robotic surgery with laser for head and neck cancers: A feasibility study. Orl 2012, 74, 124–128. [CrossRef] [PubMed]
8. Van Abel, K.M.; Moore, E.J.; Carlson, M.L.; Davidson, J.A.; Garcia, J.J.; Olsen, S.M.; Olsen, K.D. Transoral robotic surgery using the thulium:YAG laser—A Prospective Study. Arch. Otolaryngol. Head Neck Surg. 2012, 138, 158–166. [CrossRef]
9. Karaman, M.; Gün, T.; Temelkuran, B.; Aynac, E.; Kaya, C.; Tekin, A.M. Comparison of fiber delivered CO2 laser and electrocautery in transoral robot assisted tongue base surgery. Eur. Arch. OtoRinoLaryngol. 2017, 274, 2273–2279. [CrossRef]
10. Amin, M.; Edge, S.; Greene, F. AJCC Cancer Staging Manual, 8th ed.; Springer: New York, NY, USA, 2017.
11. Solares, C.A.; Strome, M. Transoral Robot-Assisted CO2 Laser Supraglottic Laryngectomy: Experimental and Clinical Data. Laryngoscope 2007, 117, 817–820. [CrossRef] [PubMed]
12. Hutcheson, K.A.; Holsinger, F.C.; Kupferman, M.E.; Lewin, J.S. Functional outcomes after TORS for oropharyngeal cancer: A systematic review. *Eur. Arch. OtoRhinolaryngol*. 2014, 272, 463–471. [CrossRef] [PubMed]

13. Mercante, G.; Ruscito, P.; Pellini, R.; Cristalli, G.; Spriano, G. Transoral robotic surgery (TORS) for tongue base tumours. *Acta Otorhinolaryngol. Ital.* 2013, 33, 230–235. [PubMed]

14. Remacle, M.; Matar, N.; Lawson, G.; Bachy, V.; Delos, M.; Nollevaux, M.C. Combining a new CO2 laser wave guide with transoral robotic surgery: A feasibility study on four patients with malignant tumors. *Eur. Arch. OtoRhinolaryngol*. 2012, 269, 1833–1837. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).